{
    "title": "112_hr6502",
    "content": "The Act titled \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" promotes the development of combinations of investigational new drugs for serious diseases by providing marketing exclusivity and priority review for significant drug combinations. The Act \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" allows the Secretary to designate a combination of drugs as significant if it includes 2 or more drugs that offer potential advancement in treating serious diseases and meet criteria for codevelopment as specified by the FDA. The Secretary can designate a drug combination as significant if it includes at least 2 unapproved drugs to encourage codevelopment. Task force recommendations are considered, and manufacturers can request a determination on a drug combination's significance within 30 days. The Secretary will review requests for drug combination designation within 30 days. If the combination meets requirements, it will be designated as a significant drug combination. The Secretary will review requests for drug combination designation within 30 days. If the combination meets requirements, it will be designated as a significant drug combination. Requests for designation must be made concurrently with or after submitting an application for drug investigation under specific sections of the Public Health Service Act. The Secretary will develop and publish an initial list of significant drug combinations within 180 days of the enactment of the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012. This list will be updated annually to include new significant drug combinations and exclude others. The Secretary will designate significant drug combinations under subsection (a) and exclude combinations no longer meeting the requirements. Market exclusivity for approved drugs in designated combinations will be extended by 6 months. The market exclusivity for approved drugs in designated significant drug combinations can be extended by 6 months under certain conditions, such as for a supplement to an application under section 505(b) or for a subsequent application for a change that results in a new indication or route of administration. The FDA grants priority review for drugs in significant drug combinations, ensuring action on applications within 6 months. \"Significantly advance treatment\" refers to treating life-threatening conditions without existing therapies or improving upon available treatments. The FDA grants priority review for drugs in significant drug combinations, ensuring action on applications within 6 months. These combinations must demonstrate improved effects on serious outcomes of diseases compared to alternative therapies, such as superiority or minimizing drug resistance. SEC. 3. CODEVELOPMENT TASK FORCE. Establishment of an interagency task force by the Secretary of Health and Human Services within 6 months of the Act's enactment to promote codevelopment of drugs in significant combinations. Task force membership includes experts in research and drug development for serious diseases like cancer. Duties include recommending significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. Public input on the recommended list is required. The interagency task force established by the Secretary of Health and Human Services will develop a list of significant drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. This list will be made publicly available for comments, revised based on feedback, and updated annually. Additionally, a policy report will be submitted one year after the Act's enactment and annually thereafter. The interagency task force will submit a policy report annually to the Secretary and Congress, identifying challenges and opportunities for codeveloping drugs in significant combinations, along with recommendations for policy changes to support this effort. The task force will publicly release a draft of the report for public comment before submitting it. The Federal Advisory Committee Act does not apply to the task force's duration. A \"significant drug combination\" refers to a combination of drugs that can advance treatment for serious diseases and meet codevelopment criteria outlined by the FDA. The task force will release a draft report for public comment before submission. A \"significant drug combination\" includes at least 2 unapproved drugs meeting FDA codevelopment criteria. The Secretary of Health and Human Services will conduct a study on the impact of exclusivity extensions on significant drug combinations. Interim findings will be shared with the task force and the public for comments. Final findings will be submitted to Congress within 5 years of the Act's enactment."
}